295 related articles for article (PubMed ID: 30962310)
1. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.
Tan SF; Dunton W; Liu X; Fox TE; Morad SAF; Desai D; Doi K; Conaway MR; Amin S; Claxton DF; Wang HG; Kester M; Cabot MC; Feith DJ; Loughran TP
J Lipid Res; 2019 Jun; 60(6):1078-1086. PubMed ID: 30962310
[TBL] [Abstract][Full Text] [Related]
2. Acid ceramidase is upregulated in AML and represents a novel therapeutic target.
Tan SF; Liu X; Fox TE; Barth BM; Sharma A; Turner SD; Awwad A; Dewey A; Doi K; Spitzer B; Shah MV; Morad SA; Desai D; Amin S; Zhu J; Liao J; Yun J; Kester M; Claxton DF; Wang HG; Cabot MC; Schuchman EH; Levine RL; Feith DJ; Loughran TP
Oncotarget; 2016 Dec; 7(50):83208-83222. PubMed ID: 27825124
[TBL] [Abstract][Full Text] [Related]
3. Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.
Marcelletti JF; Sikic BI; Cripe LD; Paietta E
Cytometry B Clin Cytom; 2019 Jan; 96(1):57-66. PubMed ID: 30334334
[TBL] [Abstract][Full Text] [Related]
4. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).
Tang R; Faussat AM; Perrot JY; Marjanovic Z; Cohen S; Storme T; Morjani H; Legrand O; Marie JP
BMC Cancer; 2008 Feb; 8():51. PubMed ID: 18271955
[TBL] [Abstract][Full Text] [Related]
5. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
[TBL] [Abstract][Full Text] [Related]
6. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
[TBL] [Abstract][Full Text] [Related]
7. Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells.
Prenkert M; Uggla B; Tina E; Tidefelt U; Strid H
Anticancer Res; 2009 Oct; 29(10):4071-6. PubMed ID: 19846953
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia cells MOLM-13 and SKM-1 established for resistance by azacytidine are crossresistant to P-glycoprotein substrates.
Messingerova L; Imrichova D; Kavcova H; Turakova K; Breier A; Sulova Z
Toxicol In Vitro; 2015 Oct; 29(7):1405-15. PubMed ID: 26009263
[TBL] [Abstract][Full Text] [Related]
9. Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60/ADR cells via inhibition of the PI3K/Akt signaling pathway.
Lin KN; Jiang YL; Zhang SG; Huang SY; Li H
Biomed Pharmacother; 2020 May; 125():109885. PubMed ID: 32007917
[TBL] [Abstract][Full Text] [Related]
10. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Ho MM; Hogge DE; Ling V
Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
[TBL] [Abstract][Full Text] [Related]
11. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.
Tang R; Cohen S; Perrot JY; Faussat AM; Zuany-Amorim C; Marjanovic Z; Morjani H; Fava F; Corre E; Legrand O; Marie JP
BMC Cancer; 2009 Jun; 9():199. PubMed ID: 19549303
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of SCN5A overcomes ABC transporter-mediated multidrug resistance in acute myeloid leukemia through promoting apoptosis.
Xu K; Zhuang XX; Shi XW
Expert Rev Hematol; 2024; 17(1-3):87-94. PubMed ID: 38230679
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitization by 4-hydroxyphenyl retinamide-induced NF-κB inhibition in acute myeloid leukemia cells.
Zhang H; Xu H; Zhang R; Zhao X; Liang M; Wei F
Cancer Chemother Pharmacol; 2020 Aug; 86(2):257-266. PubMed ID: 32696214
[TBL] [Abstract][Full Text] [Related]
14. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.
Hu XF; Slater A; Kantharidis P; Rischin D; Juneja S; Rossi R; Lee G; Parkin JD; Zalcberg JR
Blood; 1999 Jun; 93(12):4086-95. PubMed ID: 10361105
[TBL] [Abstract][Full Text] [Related]
15. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
16. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
den Boer ML; Pieters R; Kazemier KM; Rottier MM; Zwaan CM; Kaspers GJ; Janka-Schaub G; Henze G; Creutzig U; Scheper RJ; Veerman AJ
Blood; 1998 Mar; 91(6):2092-8. PubMed ID: 9490695
[TBL] [Abstract][Full Text] [Related]
17. The role of drug efflux pumps in acute myeloid leukemia.
van der Kolk DM; de Vries EG; Müller M; Vellenga E
Leuk Lymphoma; 2002 Apr; 43(4):685-701. PubMed ID: 12153153
[TBL] [Abstract][Full Text] [Related]
18. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
[TBL] [Abstract][Full Text] [Related]
19. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).
Omsland M; Bruserud Ø; Gjertsen BT; Andresen V
Oncotarget; 2017 Jan; 8(5):7946-7963. PubMed ID: 27974700
[TBL] [Abstract][Full Text] [Related]
20. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
van der Holt B; Löwenberg B; Burnett AK; Knauf WU; Shepherd J; Piccaluga PP; Ossenkoppele GJ; Verhoef GE; Ferrant A; Crump M; Selleslag D; Theobald M; Fey MF; Vellenga E; Dugan M; Sonneveld P
Blood; 2005 Oct; 106(8):2646-54. PubMed ID: 15994288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
